Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile NTRK1 fusion
Therapy Larotrectinib
Indication/Tumor Type pancreatic cancer
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 fusion pancreatic cancer sensitive Larotrectinib Case Reports/Case Series Actionable In a combined analysis of 3 clinical trials, Vitrakvi (larotrectinib) treatment resulted in partial response in a patient with pancreatic cancer harboring NTRK1 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). 29466156 detail...
NTRK1 fusion pancreatic cancer sensitive Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as third-line therapy for patients with pancreatic cancer harboring an NTRK fusion (PMID: 41067164; ESMO.org). detail... 41067164
NTRK1 fusion pancreatic cancer sensitive Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic pancreatic cancer harboring an NTRK fusion (PMID: 37678671; ESMO.org). detail... 37678671
PubMed Id Reference Title Details
(29466156) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. Full reference...
O-020 - Activity of larotrectinib in patients with TRK fusion GI malignancies Full reference...
ESMO Clinical Practice Guidelines Full reference...
ESMO Clinical Practice Guidelines Full reference...
(37678671) Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Full reference...
(41067164) Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Full reference...